Facilities

Phase 1 Capability

Phase 1 population

Adult solid tumours

Mechanisms studied

  • Bisphosphonates
  • RANK ligand inhibitors
  • CD56 targeted antibody
  • Taxanes
  • Diaphorase inhibitor
  • TKI inhibitors

First-in-Man studies

Yes

Centre specific translational research interest

Bone oncology, vascular biology, lung cancer biology

Multi-centre Phase 1 studies

Yes

 

Technology/equipment available within the centre

  • MRI, CT
  • DNA sequencing (Applied Biosystems 3730 capillary sequencer)
  • SNP genotyping Quantitative RT-PCR (384-well Applied Biosystems 7900HT platform)
  • Mutation detection (Transgenomic WAVE dHPLC)
  • High-throughput robotic screening lab (Genetix Q-bot and MegaPix)
  • Expression and SNP analysis (Affymetrix Genechip hybridisation system)
  • Flow cytometry (Becton Dickenson FACSort and FACSAria)
  • SELDI and MALDI-TOF mass spectrometry
  • Core hisopathology facilities including tissue microarrays
 

Other Facilities (e.g. Wellcome Trust CRF)

  • Purpose-built cancer clinical trials centre
  • Hospital CRF
  • BioBank
 

Sample collection

Tissue Banking Activities

Dedicated biobank
Prof FC Hamdy

Other equipment/ facilities not on site

PET scanning